BOSTON (updated June 9) — Lixisenatide (Lyxumia, Sanofi), an injectable glucagonlike peptide (GLP-1) agonist used for the treatment of type 2 diabetes, did not show a benefit on cardiovascular ...
Results are the first from a cardiovascular safety trial in the GLP-1 agonist class. A commentator at the 75th Scientific Sessions of the American Diabetes Association asked whether the FDA-mandated ...
Results first presented at the American Diabetes Association in June are published. The new drug application has since been filed at FDA. Results from the ELIXA trial, which showed that the GLP-1 ...
In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, ...
Back in 2013, Sanofi ($SNY) pulled its FDA application for Lyxumia (lixisenatide), a GLP-1 diabetes fighter set to compete with the likes of Novo Nordisk's ($NVO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results